At EuroPCR 2023, presentations of the 3-year LEADERS FREE III report and the 12-month ASIAN STEMI Registry showed outstanding safety and efficacy profiles for the BioFreedom™ Family of stents in HBR and STEMI patients, respectively.

https://www.biosensors.com/platform/enews/e-News/News2308/ASIAN-STEMI_1yr_EUROPCR_2023.pdf

https://www.biosensors.com/platform/enews/e-News/News2308/LEADERS-FREE-III_3year_EUROPCR_2023_Eberli.pdf

The LEADERS FREE III 3-year follow up strengthened the safety and efficacy profile of BioFreedom™ Ultra in HBR patients treated with 1-month DAPT, due to superior efficacy compared with BioFreedom™ in stainless steel and a numerically lower rate of MI, CD and ST. With this presentation, among all trials conducted in HBR patients with BA9™ DCS, including more than 13,000 patients and 2 different RCTs, 3 studies now have long-term follow up available: LEADERS FREE, ONYX ONE GLOBAL and LEADERS FREE III. Also, long-term data shows that better results of the Ultra platform in CoCr over stainless steel increase over time. In parallel, the primary endpoint of the ASIAN STEMI Registry showed a very low rate of TLF and def-prob ST in 914 all-comers STEMI patients. Thanks to this new report, we now have 3 different trials focused on ACS patients, both HBR and Non-HBR, confirming the excellent safety and efficacy profile of BA9™ DCS: LEADERS FREE ACS, BESAMI MUCHO and ASIAN STEMI Registry.

29/08/2023